From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Vestipitant structure.svg
Clinical data
ATC code
  • None
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass545.416 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Vestipitant (INN)[1]:98 is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug,[2][3] and as a treatment for tinnitus[4] and insomnia.[5]

See also[edit]


  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). World Health Organization. Retrieved 17 November 2016.
  2. ^ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive cancer therapy. 3 (3): 140–2. doi:10.3816/SCT.2006.n.011. PMID 18632487.
  3. ^ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR; et al. (2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European Neuropsychopharmacology. 18 (10): 729–50. doi:10.1016/j.euroneuro.2008.06.002. PMID 18657401.
  4. ^ Clinical trial number NCT00394056 for "Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss" at
  5. ^ Ratti, E; et al. (December 2013). "Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia". Sleep. 36 (12): 1823–30. doi:10.5665/sleep.3208. PMC 3825431. PMID 24293756.